Are you invested in Accelerate Diagnostics (AXDX)?
What’s up with Accelerate Diagnostics?
Accelerate Diagnostics (AXDX) opened at $10.45, which means the stock is down 4.32% from yesterday’s closing price of 10.51. Today, the company has a high of $10.49 and a low of $9.95. The company has a market cap of $565.30 million with a 52-week high of $16.82 and a 52-week low of $4.47.
What about the future for Accelerate Diagnostics?
The high forecast for Accelerate Diagnostics is $29.00 while the low is $17.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. Accelerate Diagnostics has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information AXDX seems to be a safe buy.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.